Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reproductive Biology and Endocrinology
Published in: Reproductive Biology and Endocrinology 1/2010

Open Access 01-12-2010 | Research

Altered placental expression of PAPPA2 does not affect birth weight in mice

Authors: Pamela K Wagner, Julian K Christians

Published in: Reproductive Biology and Endocrinology | Issue 1/2010

Login to get access

Abstract

Background

Pregnancy-associated plasma protein A2 (PAPPA2) is an insulin-like growth factor binding protein (IGFBP) protease expressed in the placenta and upregulated in pregnancies complicated by pre-eclampsia. The mechanism linking PAPPA2 expression and pre-eclampsia and the consequences of altered PAPPA2 expression remain unknown. We previously identified PAPPA2 as a candidate gene for a quantitative trait locus (QTL) affecting growth in mice and in the present study examined whether this QTL affects placental PAPPA2 expression and, in turn, placental or embryonic growth.

Methods

Using a line of mice that are genetically homogenous apart from a 1 megabase QTL region containing the PAPPA2 gene, we bred mice homozygous for alternate QTL genotypes and collected and weighed placentae and embryos at E12.5. We used quantitative RT-PCR to measure the mRNA levels of PAPPA2, as well as mRNA levels of IGFBP-5 (PAPPA2's substrate), and PAPPA (a closely related IGFBP protease) to examine potential feedback and compensation effects. Western blotting was used to quantify PAPPA2 protein. Birth weight was measured in pregnancies allowed to proceed to parturition.

Results

PAPPA2 mRNA and protein expression levels in the placenta differed by a factor of 2.5 between genotypes, but we did not find a significant difference between genotypes in embryonic PAPPA2 mRNA levels. Placental IGFBP-5 and PAPPA mRNA expression levels were not altered in response to PAPPA2 levels, and we could not detect IGFBP-5 protein in the placenta by Western blotting. The observed difference in placental PAPPA2 expression had no significant effect on placental or embryonic mass at mid-gestation, birth weight or litter size.

Conclusions

Despite a significant difference between genotypes in placental PAPPA2 expression similar in magnitude to the difference between pre-eclamptic and normal placentae previously reported, we observed no difference in embryonic, placental or birth weight. Our results suggest that elevated PAPPA2 levels are a consequence, rather than a cause, of pregnancy complications.
Appendix
Available only for authorised users
Literature
1.
Fowden AL: The insulin-like growth factors and feto-placental growth. Placenta. 2003, 24: 803-812. 10.1016/S0143-4004(03)00080-8.CrossRefPubMed
2.
Baxter RC: Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab. 2000, 278: E967-76.PubMed
3.
Bunn RC, Fowlkes JL: Insulin-like growth factor binding protein proteolysis. Trends Endocrinol Metab. 2003, 14: 176-181. 10.1016/S1043-2760(03)00049-3.CrossRefPubMed
4.
Murphy LJ: Insulin-like growth factor-binding proteins: functional diversity or redundancy?. J Mol Endocrinol. 1998, 21: 97-107. 10.1677/jme.0.0210097.CrossRefPubMed
5.
Giudice LC, Conover CA, Bale L, Faessen GH, Ilg K, Sun I, Imani B, Suen LF, Irwin JC, Christiansen M, Overgaard MT, Oxvig C: Identification and regulation of the IGFBP-4 protease and its physiological inhibitor in human trophoblasts and endometrial stroma: evidence for paracrine regulation of IGF-II bioavailability in the placental bed during human implantation. J Clin Endocrinol Metab. 2002, 87: 2359-2366. 10.1210/jc.87.5.2359.CrossRefPubMed
6.
Sun IY, Overgaard MT, Oxvig C, Giudice LC: Pregnancy-associated plasma protein A proteolytic activity is associated with the human placental trophoblast cell membrane. J Clin Endocrinol Metab. 2002, 87: 5235-5240. 10.1210/jc.2002-020561.CrossRefPubMed
7.
Fialova L, Malbohan IM: Pregnancy-associated plasma protein A (PAPP-A): theoretical and clinical aspects. Bratisl Lek Listy. 2002, 103: 194-205.PubMed
8.
Brambati B, Macintosh MC, Teisner B, Maguiness S, Shrimanker K, Lanzani A, Bonacchi I, Tului L, Chard T, Grudzinskas JG: Low maternal serum levels of pregnancy associated plasma protein A (PAPP-A) in the first trimester in association with abnormal fetal karyotype. Br J Obstet Gynaecol. 1993, 100: 324-326.CrossRefPubMed
9.
Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM: Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab. 2002, 87: 1762-1767. 10.1210/jc.87.4.1762.CrossRefPubMed
10.
Spencer K, Yu CKH, Cowans NJ, Otigbah C, Nicolaides KH: Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn. 2005, 25: 949-953. 10.1002/pd.1251.CrossRefPubMed
11.
Bersinger NA, Odegard RA: Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand. 2004, 83: 37-45.CrossRefPubMed
12.
Cowans NJ, Spencer K: First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system. Prenat Diagn. 2007, 27: 264-271. 10.1002/pd.1665.CrossRefPubMed
13.
Farr M, Strube J, Geppert HG, Kocourek A, Mahne M, Tschesche H: Pregnancy-associated plasma protein-E (PAPP-E). Biochim Biophys Acta. 2000, 1493: 356-362.CrossRefPubMed
14.
Overgaard MT, Boldt HB, Laursen LS, Sottrup-Jensen L, Conover CA, Oxvig C: Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase. J Biol Chem. 2001, 276: 21849-21853. 10.1074/jbc.M102191200.CrossRefPubMed
15.
Boldt HB, Conover CA: Pregnancy-associated plasma protein-A (PAPP-A): a local regulator of IGF bioavailability through cleavage of IGFBPs. Growth Horm IGF Res. 2007, 17: 10-18. 10.1016/j.ghir.2006.11.003.CrossRefPubMed
16.
Yan X, Baxter RC, Firth SM: Involvement of Pregnancy-Associated Plasma Protein-A2 in Insulin-Like Growth Factor (IGF) Binding Protein-5 Proteolysis during Pregnancy: A Potential Mechanism for Increasing IGF Bioavailability. J Clin Endocrinol Metab. 2010, 95: 1412-1420. 10.1210/jc.2009-2277.CrossRefPubMed
17.
Buimer M, Keijser R, Jebbink JM, Wehkamp D, van Kampen AH, Boer K, van der Post JA, Ris-Stalpers C: Seven placental transcripts characterize HELLP-syndrome. Placenta. 2008, 29: 444-453. 10.1016/j.placenta.2008.02.007.CrossRefPubMed
18.
Nishizawa H, Pryor-Koishi K, Suzuki M, Kato T, Kogo H, Sekiya T, Kurahashi H, Udagawa Y: Increased levels of pregnancy-associated plasma protein-A2 in the serum of pre-eclamptic patients. Mol Hum Reprod. 2008, 14: 595-602. 10.1093/molehr/gan054.CrossRefPubMed
19.
Sitras V, Paulssen RH, Grønaas H, Leirvik J, Hanssen TA, Vårtun A, Acharya G: Differential Placental Gene Expression in Severe Preeclampsia. Placenta. 2009, 30: 424-433. 10.1016/j.placenta.2009.01.012.CrossRefPubMed
20.
Winn VD, Gormley M, Paquet AC, Kjar-Sorensen K, Kramer A, Rumer KK, Haimov-Kochman R, Yeh RF, Overgaard MT, Varki A, Oxvig C, Fisher SJ: Severe Preeclampsia-Related Changes in Gene Expression at the Maternal-Fetal Interface Include Siglec-6 and Pappalysin-2. Endocrinology. 2009, 150: 452-462. 10.1210/en.2008-0990.PubMedCentralCrossRefPubMed
21.
Christians JK, Gruslin A: Altered levels of insulin-like growth factor binding protein proteases in preeclampsia and intrauterine growth restriction. Prenat Diagn. in press
22.
Schneider MR, Wolf E, Hoeflich A, Lahm H: IGF-binding protein-5: flexible player in the IGF system and effector on its own. J Endocrinol. 2002, 172: 423-440. 10.1677/joe.0.1720423.CrossRefPubMed
23.
Wang J, Qiu Q, Haider M, Bell M, Gruslin A, Christians JK: Expression of pregnancy associated plasma protein A2 (PAPPA2) during pregnancy in human and mouse. J Endocrinol. 2009, 202: 337-345. 10.1677/JOE-09-0136.CrossRefPubMed
24.
Christians JK, Hoeflich A, Keightley PD: PAPPA2, an enzyme that cleaves an insulin-like growth-factor-binding protein, is a candidate gene for a quantitative trait locus affecting body size in mice. Genetics. 2006, 173: 1547-1553. 10.1534/genetics.106.057513.PubMedCentralCrossRefPubMed
25.
Sibai BM, Ewell M, Levine RJ, Klebanoff MA, Esterlitz J, Catalano PM, Goldenberg RL, Joffe G: Risk factors associated with preeclampsia in healthy nulliparous women. Am J Obstet Gynecol. 1997, 177: 1003-1010. 10.1016/S0002-9378(97)70004-8.CrossRefPubMed
26.
Cross JC: The genetics of pre-eclampsia: a feto-placental or maternal problem?. Clin Genet. 2003, 64: 96-103. 10.1034/j.1399-0004.2003.00127.x.CrossRefPubMed
27.
Lachmeijer AMA, Dekker GA, Pals G, Aarnoudse JG, ten Kate LP, Arngrimsson R: Searching for preeclampsia genes: the current position. Eur J Obstet Gynecol Reprod Biol. 2002, 105: 94-113.CrossRefPubMed
28.
Kaufmann P, Black S, Huppertz B: Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod. 2003, 69: 1-7. 10.1095/biolreprod.102.014977.CrossRefPubMed
29.
30.
Conover CA, Bale LK, Overgaard MT, Johnstone EW, Laursen UH, Fuchtbauer EM, Oxvig C, van Deursen J: Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal development. Development. 2004, 131: 1187-1194. 10.1242/dev.00997.CrossRefPubMed
31.
Qin X, Sexton C, Byun D, Strong DD, Baylink DJ, Mohan S: Differential regulation of pregnancy associated plasma protein (PAPP)-A during pregnancy in human and mouse. Growth Horm IGF Res. 2002, 12: 359-366. 10.1016/S1096-6374(02)00046-1.CrossRefPubMed
32.
Soe R, Overgaard MT, Thomsen AR, Laursen LS, Olsen IM, Sottrup-Jensen L, Haaning J, Giudice LC, Conover CA, Oxvig C: Expression of recombinant murine pregnancy-associated plasma protein-A (PAPP-A) and a novel variant (PAPP-Ai) with differential proteolytic activity. Eur J Biochem. 2002, 269: 2247-2256. 10.1046/j.1432-1033.2002.02883.x.CrossRefPubMed
33.
Gilpin BJ, Loechel F, Mattei MG, Engvall E, Albrechtsen R, Wewer UM: A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo. J Biol Chem. 1998, 273: 157-166. 10.1074/jbc.273.1.157.CrossRefPubMed
34.
Loechel F, Fox JW, Murphy G, Albrechtsen R, Wewer UM: ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun. 2000, 278: 511-515. 10.1006/bbrc.2000.3835.CrossRefPubMed
35.
Shi Z, Xu W, Loechel F, Wewer UM, Murphy LJ: ADAM 12, a disintegrin metalloprotease, interacts with insulin-like growth factor-binding protein-3. J Biol Chem. 2000, 275: 18574-18580. 10.1074/jbc.M002172200.CrossRefPubMed
36.
Spencer K, Cowans NJ, Stamatopoulou A: ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenat Diagn. 2008, 28: 212-216. 10.1002/pd.1957.CrossRefPubMed
37.
Kurisaki T, Masuda A, Sudo K, Sakagami J, Higashiyama S, Matsuda Y, Nagabukuro A, Tsuji A, Nabeshima Y, Asano M, Iwakura Y, Sehara-Fujisawa A: Phenotypic analysis of Meltrin alpha (ADAM12)-deficient mice: involvement of Meltrin alpha in adipogenesis and myogenesis. Mol Cell Biol. 2003, 23: 55-61. 10.1128/MCB.23.1.55-61.2003.PubMedCentralCrossRefPubMed
Metadata
Title
Altered placental expression of PAPPA2 does not affect birth weight in mice
Authors
Pamela K Wagner
Julian K Christians
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Reproductive Biology and Endocrinology / Issue 1/2010
Electronic ISSN: 1477-7827
DOI
https://doi.org/10.1186/1477-7827-8-90

Other articles of this Issue 1/2010

Reproductive Biology and Endocrinology 1/2010 Go to the issue

Debate

Health implications resulting from the timing of elective cesarean delivery

Research

Transforming growth factor beta family expression at the bovine feto-maternal interface

Research

Vascular endothelial growth factor-D over-expressing tumor cells induce differential effects on uterine vasculature in a mouse model of endometrial cancer

Research

Different levels of overnutrition and weight gain during pregnancy have differential effects on fetal growth and organ development

Methodology

Discontinuation of rLH two days before hCG may increase the number of oocytes retrieved in IVF

Debate

The impact of fetal gender on prematurity in dichorionic twin gestations after in vitro fertilization